var title_f39_16_40192="Bullous pemphigoid 2";
var content_f39_16_40192=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F69828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F69828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bullous pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 82-year-old female with bullous pemphigoid exhibited pruritic, tense bullae with underlying erythema on the arms, trunk, and legs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Katsuya Hisamichi, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_16_40192=[""].join("\n");
var outline_f39_16_40192=null;
var title_f39_16_40193="Laparoscopic resection of the stomach from the hernia sac";
var content_f39_16_40193=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F61860&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F61860&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Laparoscopic resection of the stomach from the hernia sac",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This intraoperative photograph shows the stomach being retracted from the paraesophageal hernia sac. The arrows identify the defect in the diaphragm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Rosen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_16_40193=[""].join("\n");
var outline_f39_16_40193=null;
var title_f39_16_40194="Ioxaglate meglumine and ioxaglate sodium: Drug information";
var content_f39_16_40194=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ioxaglate meglumine and ioxaglate sodium: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/18/3364?source=see_link\">",
"    see \"Ioxaglate meglumine and ioxaglate sodium: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F184042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hexabrix&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F184045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Iodinated Contrast Media;",
"     </li>",
"     <li>",
"      Radiological/Contrast Media (Ionic, Low Osmolality)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15962290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. Use caution in severe impairment and in setting of combined renal and hepatic disease.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15962291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. Use caution in patients with combined hepatic and renal disease.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F184034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hexabrix&trade;: Ioxaglate meglumine 39.3% and ioxaglate sodium 19.6% (20 mL, 50 mL, 100 mL, 150 mL, 200 mL) [provides organically-bound iodine 32% (320 mg/mL); contains edetate calcium disodium, sodium 3.48 mg (0.15 mEq)/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F184030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F13791583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Fenoldopam.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Ampicillin, chloramphenicol, epinephrine, heparin, hydrocortisone sodium succinate, methylprednisolone sodium succinate.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Cimetidine, diphenhydramine, protamine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Gentamicin, papaverine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F184035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Angiocardiography, arteriography, aortography, arthrography, angiography, hysterosalpingography, venography, and urography procedures; contrast enhancement of computed tomographic imaging",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5174554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F184037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ioxaglate or any component of the formulation; myelography; hysterosalpingography during the menstrual period, pregnancy, genital tract infection, or  cervical conization or curettage within 30 days; arthrography with infection present in or near the joint",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F184032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F184039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies did not show fetal harm. In general, iodinated contrast media agents are avoided during pregnancy unless essential for diagnosis.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F184043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F184040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bottle feedings are recommended for 24 hours after administration.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9732468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Hexabrix (AT, BE, CH, CZ, DE, DK, FI, FR, GB, GR, HN, IT, NL, NO, NZ, PT, SE, SG, TR)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Committee on Obstetric Practice, &ldquo;ACOG Committee Opinion. Guidelines for Diagnostic Imaging During Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2004, 104(3):647-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/16/40194/abstract-text/15339791/pubmed\" id=\"15339791\" target=\"_blank\">",
"        15339791",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jneid H, Anderson JL, Wright RS, et al, &ldquo;2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(7):875-910.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/16/40194/abstract-text/22800849/pubmed\" id=\"22800849\" target=\"_blank\">",
"        22800849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klein LW, Sheldon MW, Brinker J, et al, &ldquo;The Use of Radiographic Contrast Media During PCI: A Focused Review: A Position Statement of the Society of Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Catheter Cardiovasc Interv",
"      </i>",
"      , 2009, 74(4):728-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/16/40194/abstract-text/19830793/pubmed\" id=\"19830793\" target=\"_blank\">",
"        19830793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Laskey WK, Jenkins C, Selzer F, et al, &ldquo;Volume-to-Creatinine Clearance Ratio: A Pharmacokinetically Based Risk Factor for Prediction of Early Creatinine Increase After Percutaneous Coronary Intervention,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 50(7):584-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/16/40194/abstract-text/17692741/pubmed\" id=\"17692741\" target=\"_blank\">",
"        17692741",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):e574-651.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/16/40194/abstract-text/22064601/pubmed\" id=\"22064601\" target=\"_blank\">",
"        22064601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8969 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-0D0D3C1A28-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_16_40194=[""].join("\n");
var outline_f39_16_40194=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184042\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184045\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962290\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962291\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184034\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184030\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13791583\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184035\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174554\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184037\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184032\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184039\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184043\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184040\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9732468\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038662\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8969\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8969|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/18/3364?source=related_link\">",
"      Ioxaglate meglumine and ioxaglate sodium: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_16_40195="Heart attack";
var content_f39_16_40195=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Heart attack (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?39/16/40195/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/16/40195/contributors\" id=\"au5414\">",
"       Guy S Reeder, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/16/40195/contributors\" id=\"au334\">",
"       Jeffrey A Breall, MD, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?39/16/40195/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/16/40195/contributors\" id=\"se4323\">",
"       Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?39/16/40195/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/16/40195/contributors\" id=\"de1101\">",
"       Gordon M Saperia, MD, FACC",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/16/40195?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      HEART ATTACK OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     The heart, like all other organs and tissues in the body, requires a supply of blood. The blood supply to the heart is provided by blood vessels called the coronary arteries. The coronary arteries lie on the outside of the heart muscle before entering the heart muscle itself (",
"     <a class=\"graphic graphic_figure graphicRef67870 \" href=\"mobipreview.htm?41/30/42466\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Myocardial infarction, or MI (commonly known as a \"heart attack\"), is damage or death of part of the heart muscle. The damage is caused by lack of blood flow through the coronary arteries. For this reason, an MI is sometimes also called a \"coronary.\" Almost all cases of MI occur in someone who has an underlying condition called coronary heart disease (CHD).",
"    </p>",
"    <p>",
"     More detailed information about heart attack is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=see_link\">",
"      \"Overview of the acute management of ST elevation myocardial infarction\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=see_link\">",
"      \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2\">",
"     <span class=\"h2\">",
"      Coronary heart disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;In people with coronary heart disease, sometimes called coronary artery disease or coronary disease, the coronary arteries become narrowed by fatty deposits called plaques (",
"     <a class=\"graphic graphic_figure graphicRef78702 \" href=\"mobipreview.htm?3/9/3219\">",
"      figure 2",
"     </a>",
"     ). The fatty plaques inside the coronary arteries limit blood flow to the heart muscle, which may cause pain or tightness in the chest. This pain or tightness is called angina pectoris, commonly referred to as \"angina\".",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Plaque rupture and clot formation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Normally, plaques that have built up on the artery walls hold together and stay stuck there. Sometimes, however, plaques can develop cracks in their surface. If that happens, the body responds as though the blood vessel is injured and bleeding. As part of the body's \"first aid\" response, tiny blood elements called platelets travel to the site and begin sticking to one another to form a clot (",
"     <a class=\"graphic graphic_figure graphicRef60394 \" href=\"mobipreview.htm?3/16/3331\">",
"      figure 3",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Normally, clots like these are a good thing, because they stop you from bleeding. Unfortunately, when clots form inside the coronary arteries, they can get lodged there and partially or completely block the flow of blood. This is what happens during a heart attack.",
"    </p>",
"    <p>",
"     When a blood clot form within a coronary artery, the area of heart muscle fed by that artery no longer receives enough blood. This lack of blood supply is called \"ischemia.\" As a result of ischemia, the heart muscle becomes damaged and may die. The death of heart muscle is termed \"infarction.\"",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      HEART ATTACK SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The \"typical\" symptoms of a heart attack include:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Chest pain",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Chest pain or discomfort (pressure, tightness, or squeezing)",
"      </li>",
"      <li>",
"       Pain spreads through the chest and others areas of the body, including the upper abdomen, shoulders, arms, neck and throat, or lower jaw and teeth",
"      </li>",
"      <li>",
"       Pain comes on gradually and lasts more than a few seconds",
"      </li>",
"      <li>",
"       Lying down may make chest pain worse, while sitting up may reduce pain",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Other symptoms",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Shortness of breath",
"      </li>",
"      <li>",
"       Nausea, vomiting, or belching",
"      </li>",
"      <li>",
"       Sweating",
"      </li>",
"      <li>",
"       Palpitations (skipped heart beats)",
"      </li>",
"      <li>",
"       Lightheadedness",
"      </li>",
"      <li>",
"       Feeling tired",
"      </li>",
"      <li>",
"       Fainting",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      HEART ATTACK DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     If you have chest pain that is new, severe, prolonged, or if chest pain causes concern,",
"     <strong>",
"      call 911 immediately.",
"     </strong>",
"     The emergency medical services (EMS) personnel in your community are prepared to respond rapidly, and will take you to the nearest hospital. For a patient having a heart attack, every minute is important. Remember, the faster you get to a hospital, the sooner you can receive treatment.",
"    </p>",
"    <p>",
"     Although not everyone with chest pain is having a heart attack, you may be treated for a heart attack until testing can be done to determine the cause of your symptoms.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      HEART ATTACK TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     You will be given oxygen through a flexible plastic tube that rests beneath the nose or by a face mask, and an electrocardiogram (EKG) will be measured as quickly as possible. The EKG gives a picture of the flow of electrical activity that causes the heart to beat. Damaged areas usually show an abnormal pattern. The EKG may be repeated several times in the first few minutes to monitor for changes that may be occurring.",
"    </p>",
"    <p>",
"     Blood is drawn and sent to the laboratory to look for substances in the blood that are released by damaged heart tissue (cardiac enzymes or proteins). An intravenous line (IV) is started so that medicines can be given directly into the veins. Nitroglycerin is given either through the IV or under the tongue to relieve chest pain. Morphine may also be given to help relieve chest pain and ease your anxiety. You will be given aspirin to chew and swallow to help stop new blood clots from forming.",
"    </p>",
"    <p>",
"     There are different types of myocardial infarction (MI), based on what is seen on the EKG. The two main types are called ST elevation MI (STEMI) and non-ST elevation MI (NSTEMI). Your treatment will depend upon the type of MI you have.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Treatment of non-ST elevation heart attack",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with non-ST elevation MI are treated drugs, including aspirin, that help prevent new blood clots. A medication called a beta blocker may also be given to slow the heart and decrease the heart's demand for oxygen, and drugs such as statins are used to lower the cholesterol.",
"    </p>",
"    <p>",
"     Following this, two approaches to treatment are possible: intensive medical therapy and early catheterization.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Intensive medical therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Your condition will be stabilized with intravenous drugs. After several days, the drugs are stopped. If your symptoms do not return, exercise testing is performed. In this test, you exercise on a treadmill or bicycle, and the heart's response is examined with an EKG. The exercise test can indicate if your coronary arteries are narrowed or blocked.",
"    </p>",
"    <p>",
"     Further treatment decisions are based upon the results of the exercise test.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       You may be discharged on medicines that control your symptoms",
"      </li>",
"      <li>",
"       You may need one or more procedures, including cardiac catheterization followed by angioplasty, coronary artery stenting, or surgery (explained below).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Early catheterization",
"     </span>",
"     &nbsp;&mdash;&nbsp;With this approach, you are taken for a cardiac catheterization within the first hours or days of being in the hospital. A small plastic tube (catheter) is threaded through a blood vessel (artery), usually in the groin, to the coronary arteries. A dye is injected that allows the arteries to be seen on X-ray.",
"    </p>",
"    <p>",
"     If blockages or narrowings are found, a procedure known as percutaneous coronary intervention (also known as angioplasty or stenting) may be done. With this procedure, a tiny catheter with a balloon at the end of it is advanced into the narrowed coronary artery. The balloon is then inflated, which helps open up the narrowed artery. A stent (an expandable metal tube) may be placed in the artery to prevent the narrowing from recurring. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/38/18020?source=see_link\">",
"      \"Patient information: Heart stents and angioplasty (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     In some cases, the x-ray reveals that the blockages cannot be opened using angioplasty or stents. In these instances, coronary artery bypass graft surgery (CABG) may be an option. During the CABG operation (often pronounced \"cabbage\"), a blood vessel (vein or artery) is taken from the leg or the chest and used as a detour around the blocked coronary artery. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/62/31717?source=see_link\">",
"      \"Patient information: Coronary artery bypass graft surgery (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Treatment of ST elevation heart attack",
"     </span>",
"     &nbsp;&mdash;&nbsp;If your EKG indicates that you are having an ST elevation heart attack, you will be given many of the same medications as for NSTEMI, while deciding how best to quickly open the blocked coronary artery.",
"    </p>",
"    <p>",
"     Opening the blocked artery is called \"reperfusion therapy.\" The more quickly this therapy is given, the better the chance of saving areas of your heart that might otherwise be damaged. In general, the best outcome occurs when the artery is opened within four hours of your first heart attack symptoms, preferably within 90 to 120 minutes. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/31/37369?source=see_link\">",
"      \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Reperfusion therapy can occur in one of two ways. The preferred method is percutaneous coronary intervention, which is explained separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/38/18020?source=see_link\">",
"      \"Patient information: Heart stents and angioplasty (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     However, not every hospital is equipped to do percutaneous coronary intervention in a timely manner. In this case an acceptable alternative treatment is to use a medicine that dissolves blood clots. The clot-busting drugs, called thrombolytic or fibrinolytic agents, must be given within 30 minutes of arrival at the hospital. However, these drugs cannot be given to certain patients, including those who have active bleeding, a high blood pressure reading, recent trauma, or a history of stroke. They are also not recommended in the treatment of non-ST elevation heart attack.",
"    </p>",
"    <p>",
"     In some people with ST elevation heart attack, urgent bypass surgery is needed. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/62/31717?source=see_link\">",
"      \"Patient information: Coronary artery bypass graft surgery (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      THE DISCHARGE PLAN",
"     </span>",
"    </p>",
"    <p>",
"     If there are no complications during or after your heart attack, you can usually leave the hospital after about two to five days. You will be given information about what medications to take (old and new), lifestyle changes such as stopping smoking cessation, and you will be referred to a cardiac",
"     <span class=\"nowrap\">",
"      rehabilitation/exercise",
"     </span>",
"     program. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/52/12100?source=see_link\">",
"      \"Patient information: Heart attack recovery (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     You should take your medications exactly as directed; if you have side effects or questions about your medications, call your doctor before stopping or changing your dose.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784982522\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H112838313\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/10/27809?source=see_link\">",
"      Patient information: Coronary heart disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/12/17601?source=see_link\">",
"      Patient information: Heart failure (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/53/10068?source=see_link\">",
"      Patient information: Heart attack (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/46/6883?source=see_link\">",
"      Patient information: Shortness of breath (dyspnea) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/6/37987?source=see_link\">",
"      Patient information: Heart attack recovery (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/51/25395?source=see_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/30/32226?source=see_link\">",
"      Patient information: Nuclear heart testing (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/42/21156?source=see_link\">",
"      Patient information: Recovery after coronary artery bypass graft surgery (CABG) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/2/32803?source=see_link\">",
"      Patient information: What can go wrong after a heart attack? (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/53/35667?source=see_link\">",
"      Patient information: Cardiac catheterization (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/57/27539?source=see_link\">",
"      Patient information: High blood pressure emergencies (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/39/34419?source=see_link\">",
"      Patient information: Sudden cardiac arrest (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/5/23635?source=see_link\">",
"      Patient information: Atherosclerosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/12/25795?source=see_link\">",
"      Patient information: Ventricular fibrillation (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/38/30307?source=see_link\">",
"      Patient information: Aortic dissection (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/54/7012?source=see_link\">",
"      Patient information: Coronary heart disease in women (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/40/13956?source=see_link\">",
"      Patient information: Diastolic heart failure (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/32/7684?source=see_link\">",
"      Patient information: Systolic heart failure (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/6/35938?source=see_link\">",
"      Patient information: Stress-induced cardiomyopathy (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H112838328\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/38/18020?source=see_link\">",
"      Patient information: Heart stents and angioplasty (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/62/31717?source=see_link\">",
"      Patient information: Coronary artery bypass graft surgery (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/52/12100?source=see_link\">",
"      Patient information: Heart attack recovery (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30890?source=see_link\">",
"      Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=see_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=see_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/59/7098?source=see_link\">",
"      Overview of the non-acute management of ST elevation myocardial infarction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/33/44569?source=see_link\">",
"      Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/43/2746?source=see_link\">",
"      Risk stratification after unstable angina or non-ST elevation myocardial infarction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/52/35658?source=see_link\">",
"      Risk stratification for cardiac events after acute ST elevation myocardial infarction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=see_link\">",
"      Secondary prevention of stroke: Risk factor reduction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/20/41289?source=see_link\">",
"      Treatment of acute myocardial infarction in diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/31/37369?source=see_link\">",
"      Selecting a reperfusion strategy for acute ST elevation myocardial infarction",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/heartattack.html\">",
"      www.nlm.nih.gov/medlineplus/heartattack.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.heart.org/HEARTORG/Conditions/HeartAttack/Heart-Attack_UCM_001092_SubHomePage.jsp\">",
"      www.heart.org/HEARTORG/Conditions/HeartAttack/Heart-Attack_UCM_001092_SubHomePage.jsp",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Heart Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.heart.org/\">",
"      www.heart.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?39/16/40195/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2010.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/16/40195?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007). www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40195/abstract/2\">",
"      Cannon CP, Hand MH, Bahr R, et al. Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program. Am Heart J 2002; 143:777.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson J, Adams C, Antman E, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College or Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2007; 50:e1 www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f39_16_40195=[""].join("\n");
var outline_f39_16_40195=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           HEART ATTACK OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           HEART ATTACK SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           HEART ATTACK DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           HEART ATTACK TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           THE DISCHARGE PLAN",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/30/42466\" title=\"figure 1\">",
"           MI location PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/9/3219\" title=\"figure 2\">",
"           Plaque formation PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/16/3331\" title=\"figure 3\">",
"           Plaque rupture MI PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f39_16_40196="Mycosis fungoides poikiloderma";
var content_f39_16_40196=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F63888&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F63888&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mycosis fungoides - poikiloderma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A poikilodermatous patch exhibiting red-brown mottled pigmentation, telangiectasias, and subtle atrophy is present on the chest of this patient with mycosis fungoides.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_16_40196=[""].join("\n");
var outline_f39_16_40196=null;
var title_f39_16_40197="Prenatal ultrasound of tracheoesophageal atresia";
var content_f39_16_40197=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrasound of fetus with tracheoesophageal atresia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 302px; height: 577px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tracheoesophageal atresia with tracheoesophageal fistula at 22 weeks of gestation. The diagnosis was missed prenatally.",
"    <br>",
"     (A) Axial ultrasound demonstrates a normal sized stomach. Amniotic fluid was high normal.",
"     <br>",
"      (B) Postnatally, a tracheoesophageal atresia was discovered when the nasogastric tube (arrow) could not be advanced into the stomach. Note the large amount of air in the stomach and small bowel due to the tracheoesophageal fistula.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Courtesy of Dorothy I Bulas, MD.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_16_40197=[""].join("\n");
var outline_f39_16_40197=null;
var title_f39_16_40198="Etiology and pathogenesis of acute intermittent porphyria";
var content_f39_16_40198=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology and pathogenesis of acute intermittent porphyria",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/16/40198/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/16/40198/contributors\">",
"     Gagan K Sood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/16/40198/contributors\">",
"     Karl E Anderson, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/16/40198/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/16/40198/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/16/40198/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/16/40198/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/16/40198/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/16/40198/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute intermittent porphyria (AIP, Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is an autosomal dominant disorder resulting from a partial deficiency of porphobilinogen deaminase (PBGD, hydroxymethylbilane synthase, previously called uroporphyrinogen I synthase), the third enzyme in the heme biosynthetic pathway (",
"    <a class=\"graphic graphic_figure graphicRef68187 \" href=\"mobipreview.htm?24/31/25077\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef57890 \" href=\"mobipreview.htm?34/50/35617\">",
"     figure 2",
"    </a>",
"    ). Symptoms in AIP are due to effects on the visceral, peripheral, autonomic, and central nervous systems. They usually occur as intermittent attacks that are sometimes life-threatening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology and pathogenesis of AIP will be reviewed here. The clinical manifestations, diagnosis, and treatment of AIP and an overview of the porphyrias are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/12/10439?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute intermittent porphyria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/20/3398?source=see_link\">",
"     \"Management of acute intermittent porphyria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28984?source=see_link\">",
"     \"Porphyrias: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;AIP is the most common of the acute porphyrias worldwide, with an estimated prevalence of approximately 5 per 100,000. It occurs in all races, but may be most common in northern European countries.",
"   </p>",
"   <p>",
"    Acute porphyria was first described by Stokvis, a Dutch physician, in 1889, who recognized that the disease in his patient was precipitated by the barbiturate-related drug sulfonal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/3\">",
"     3",
"    </a>",
"    ]. Waldenstr&ouml;m noted a high prevalence of AIP in an area of northern Sweden, and established that increased excretion of the pyrrole porphobilinogen (PBG) was inherited as an autosomal dominant trait [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Earlier claims that King George III of England had AIP or variegate porphyria (VP) have been discounted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     METABOLIC DEFECT",
"    </span>",
"    &nbsp;&mdash;&nbsp;An inherited deficiency of porphobilinogen deaminase (PBGD) is the underlying cause of acute intermittent porphyria (AIP). This enzyme catalyzes the third step in the heme biosynthetic pathway, whereby four molecules of porphobilinogen (PBG) are sequentially condensed to form hydroxymethylbilane (HMB), a linear tetrapyrrole (",
"    <a class=\"graphic graphic_figure graphicRef68187 \" href=\"mobipreview.htm?24/31/25077\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef57890 \" href=\"mobipreview.htm?34/50/35617\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    PBGD has a unique cofactor, a dipyrromethane (ie, a dipyrrole) that binds the pyrrole intermediates at the catalytic site until four additional pyrroles are assembled, forming a linear hexapyrrole, after which hydroxymethylbilane (a tetrapyrrole) is released [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. It is possible that high concentrations of PBG during exacerbations of acute porphyria may inhibit formation of the holo-deaminase and further reduce hepatic enzyme activity.",
"   </p>",
"   <p>",
"    During an attack of AIP, the regulatory heme pool in the liver is depleted and there is marked induction of the housekeeping form of delta-aminolevulinic acid synthase (ALAS1), the rate-limiting enzyme for heme synthesis in the liver, leading to accumulation of delta-aminolevulinic acid (ALA) and porphobilinogen (PBG), the two intermediates proximal to the deficient enzyme.",
"   </p>",
"   <p>",
"    The ALAS1 gene contains upstream enhancer elements that respond to inducing chemicals and interact with the pregnane X receptor (PXR). Both ALAS1 and the cytochrome P450 enzymes (CYPs) are subject to direct induction by xenobiotics and steroid hormones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/8\">",
"     8",
"    </a>",
"    ]. Factors that induce hepatic heme oxygenase and accelerate the destruction of hepatic heme can also induce hepatic ALAS1. As will be described, ALAS1 is also up-regulated when calories and carbohydrate are restricted.",
"   </p>",
"   <p>",
"    ALA and PBG are colorless. However, PBG degrades to form porphobilin, a brownish product that causes dark urine. Urinary porphyrins are also increased in AIP, which accounts for reddish-brown urine. At high concentrations in urine, PBG molecules can randomly associate nonenzymatically to form a mixture of uroporphyrin isomers. However, there is evidence that porphyrins in this condition are predominantly type III, which may be formed enzymatically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/9\">",
"     9",
"    </a>",
"    ], perhaps from ALA transported to tissues other than the liver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MOLECULAR PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PBGD gene maps to chromosome 11q23-11qter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/11\">",
"     11",
"    </a>",
"    ], and consists of 15 exons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/12\">",
"     12",
"    </a>",
"    ]. Distinct erythroid-specific and housekeeping isoforms are produced through alternative splicing of two distinct primary mRNA transcripts arising from two promoters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The housekeeping promoter is upstream of exon 1 and is active in all tissues, while the erythroid-specific promoter, which is upstream of exon 2, is active only in erythroid cells. Sequences in the erythroid promoter are recognized by erythroid-specific trans-acting factors, such as GATA-1 and NF-E2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/15\">",
"     15",
"    </a>",
"    ]. The housekeeping and erythroid-specific isoforms of human PBGD contain 361 and 344 amino acid residues, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/16\">",
"     16",
"    </a>",
"    ]. Eleven of the 17 additional amino acids at the N-terminal end of the housekeeping form are encoded by exon 1, and six by a short segment of exon 3 that immediately precedes a methionine codon that initiates translation of the erythroid isoform.",
"   </p>",
"   <p>",
"    Mutations in some AIP families, such as a splice site mutation at the last position of exon 1, or a base transition in intron 1, result in decreased PBG deaminase expression in nonerythroid tissues including the liver, but not in erythroid cells, because transcription of the gene in erythroid cells starts downstream of the site of the genetic lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More than 300 mutations in PBGD gene have been recognized in AIP. Because these lead to severe loss of enzyme activity, remaining activity in heterozygotes is the product of the normal allele. There is no convincing evidence for genotype-phenotype correlation (ie, particular mutations do not predict disease severity).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MECHANISM FOR NEUROLOGICAL DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most favored explanation for the neuropathic manifestations in acute porphyrias is that one or more heme pathway intermediates, or products derived from them, are neurotoxic. Favorable experience with liver transplantation, which corrects PBGD deficiency only in the liver, supports an essential role for the liver in the neuropathic process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Circulating levels of ALA are increased in all four of the acute porphyrias (",
"    <a class=\"graphic graphic_table graphicRef51032 \" href=\"mobipreview.htm?25/1/25627\">",
"     table 1",
"    </a>",
"    ), lead poisoning, and hereditary tyrosinemia type I, which favors a neuropathic role for this porphyrin precursor, or perhaps for an ALA derivative. ALA can enter cells readily and be converted to porphyrins, which in turn may have toxic potential [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/10\">",
"     10",
"    </a>",
"    ]. ALA is also structurally similar to gamma-aminobutyric acid (GABA) and can interact with GABA receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. However, a study of ALA loading in a normal volunteer to levels seen in patients with AIP during an acute attack did not show any adverse neurologic effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is possible that PBG deaminase deficiency in the nervous system or vascular tissues may limit heme synthesis and formation of hemoproteins important for neurologic functioning. Impaired motor function and ataxia develops in mice with PBGD deficiency induced by gene targeting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/23,24\">",
"     23,24",
"    </a>",
"    ], even with normal or only slightly increased ALA in plasma and urine, suggesting a primary role for heme deficiency in porphyric neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decreased production of nitric oxide by the hemoprotein enzyme nitric oxide synthase might compromise cerebral and intestinal blood flow in AIP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. It was also suggested that impaired hepatic heme synthesis during an attack may lead to decreased activity of hepatic tryptophan pyrrolase, which might increase levels of tryptophan in plasma and brain, leading to increased synthesis of the neurotransmitter 5-hydroxytryptamine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EXACERBATING FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermittent attacks and highly variable disease expression within families is often linked to exogenous factors, such as drugs and hormones, which induce synthesis of hepatic ALA synthase 1 (ALAS1). Synthesis of this rate-limiting mitochondrial enzyme is down-regulated by a small regulatory heme pool, which is depleted when there is increased demand for heme, especially for the synthesis of heme-containing hepatic cytochromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/1\">",
"     1",
"    </a>",
"    ]. The administration of exogenous heme repletes this regulatory heme pool, rapidly down-regulating ALAS1. This forms the biochemical basis for the treatment of acute attacks of AIP with intravenous heme compounds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Drugs and chemicals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain drugs are among the most important causes of exacerbations of acute porphyrias. A partial list of drugs known to be unsafe or safe in the acute porphyrias is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef57422 \" href=\"mobipreview.htm?42/6/43116\">",
"     table 2",
"    </a>",
"    ). Most (eg, barbiturates,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    and most other antiseizure drugs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ) have the potential to induce hepatic ALAS1 and CYPs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Because information is incomplete on most drugs, sources that are frequently updated, such as the websites of the American Porphyria Foundation (",
"    <a class=\"external\" href=\"file://www.porphyriafoundation.com/\">",
"     www.porphyriafoundation.com",
"    </a>",
"    ) and the European Porphyria Network (",
"    <a class=\"external\" href=\"file://www.porphyria-europe.com/\">",
"     www.porphyria-europe.com",
"    </a>",
"    ) should be consulted whenever a patient with AIP is to be started on a new medication.",
"   </p>",
"   <p>",
"    Ethanol and other alcohols are inducers of ALAS1 and some hepatic CYPs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Smoke from tobacco and marijuana is a source of exposure to chemicals such as polycyclic aromatic hydrocarbons, and is a known inducer of hepatic CYPs and heme synthesis. An association between cigarette smoking and repeated attacks of porphyria was found in surveys of 144 patients with AIP in Britain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/31\">",
"     31",
"    </a>",
"    ] and 356 patients in Sweden [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Endocrine factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of the acute porphyrias suggest that hormones are implicated, including rarity of symptoms before puberty, more common clinical expression in women, and occurrence of attacks in some women during the luteal phase of the menstrual cycle. Certain metabolites of progesterone and testosterone and progesterone itself are potent inducers of ALAS1 and CYPs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/33\">",
"     33",
"    </a>",
"    ], and premenstrual attacks are associated with high levels of progesterone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Estrogens have less effect on hepatic heme synthesis, and have been implicated as harmful mostly in association with progesterone or progestins. Pregnancy is usually well tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/35\">",
"     35",
"    </a>",
"    ]. However, some women experience more frequent attacks, sometimes in association with reduced caloric intake or the use of certain drugs (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    for the treatment of hyperemesis gravidarum) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Effects of diabetes mellitus have not been carefully studied. Case studies suggest that high glucose levels in diabetics with AIP may decrease the frequency of attacks and lower porphyrin precursor levels (see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Nutritional factors and stress",
"    </span>",
"    &nbsp;&mdash;&nbsp;ALAS1 is up-regulated by the peroxisomal proliferator-activated cofactor 1 alpha (PGC-1alpha) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/39\">",
"     39",
"    </a>",
"    ], a co-activator of nuclear receptors and transcription factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/40\">",
"     40",
"    </a>",
"    ]. With starvation or other conditions where glucose levels are low, transcription of PGC-1alpha is up-regulated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/41,42\">",
"     41,42",
"    </a>",
"    ], in turn increasing ALAS1.",
"   </p>",
"   <p>",
"    This mechanism explains the exacerbation of AIP and other acute porphyrias by reduced intakes of calories and carbohydrate, which may occur during illness, surgery or other stress. Increases in ALA and PBG and symptoms of porphyria under such circumstances can be reversed by carbohydrate administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/39,43\">",
"     39,43",
"    </a>",
"    ], reflecting down-regulation of PGC-1alpha [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/2,44\">",
"     2,44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/20/3398?source=see_link&amp;anchor=H4#H4\">",
"     \"Management of acute intermittent porphyria\", section on 'Carbohydrate loading'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Starvation and metabolic stress may also induce hepatic heme oxygenase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/45\">",
"     45",
"    </a>",
"    ], which may deplete hepatic heme and contribute to ALAS1 induction. Psychological stress has also been implicated in causing attacks, but the mechanisms involved are not well defined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other factors and additive effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients continue to have attacks of acute porphyria after known exacerbating factors are addressed, indicating that additional factors that contribute to clinical expression of AIP remain to be identified, possibly including disease-modifying genes. Harmful factors in acute porphyrias are also additive, as evidenced by a study in Finland showing that exacerbations of porphyria by barbiturate anesthesia occurred mostly in patients who were undiagnosed but had already developed symptoms from preexisting influences, rather than in those who were completely asymptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40198/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute intermittent porphyria (AIP) is one of the four acute porphyrias (",
"      <a class=\"graphic graphic_table graphicRef51032 \" href=\"mobipreview.htm?25/1/25627\">",
"       table 1",
"      </a>",
"      ), and is caused by an inherited deficiency of porphobilinogen deaminase (PBGD), the third enzyme in the heme biosynthetic pathway (",
"      <a class=\"graphic graphic_figure graphicRef68187 \" href=\"mobipreview.htm?24/31/25077\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Metabolic defect'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Molecular pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AIP is associated with an increased production of the heme intermediates delta-aminolevulinic acid (ALA) and porphobilinogen (PBG). Neurologic dysfunction is thought to be related to the increased production of these two intermediates",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      their metabolic byproducts. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Mechanism for neurological dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute attacks of AIP are usually associated with the presence of one or more provoking factors, such as drugs and chemicals (",
"      <a class=\"graphic graphic_table graphicRef57422 \" href=\"mobipreview.htm?42/6/43116\">",
"       table 2",
"      </a>",
"      ), smoking, endocrine changes, nutritional factors (especially fasting) and stress. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Exacerbating factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations, diagnosis, and treatment of AIP are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/12/10439?source=see_link\">",
"       \"Clinical manifestations and diagnosis of acute intermittent porphyria\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/20/3398?source=see_link\">",
"       \"Management of acute intermittent porphyria\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Anderson KE, Sassa S, Bishop DF, Desnick RJ. Disorders of heme biosynthesis: X-linked sideroblastic anemias and the porphyrias. In: The Metabolic and Molecular Basis of Inherited Disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, et al. (Eds), McGraw-Hill, New York 2001. p.2991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/2\">",
"      Anderson KE, Bloomer JR, Bonkovsky HL, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 2005; 142:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/3\">",
"      Wilson JP. Stokvis and acute porphyria. Mol Aspects Med 1990; 11:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/4\">",
"      WALDENSTROM J. The porphyrias as inborn errors of metabolism. Am J Med 1957; 22:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/5\">",
"      Tschudy DP, Valsamis M, Magnussen CR. Acute intermittent porphyria: clinical and selected research aspects. Ann Intern Med 1975; 83:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/6\">",
"      Peters T. Thomas Wakley, King George III and acute porphyria. J R Soc Med 2009; 102:506.",
"     </a>",
"    </li>",
"    <li>",
"     Jordan PM. The biosynthesis of 5-aminolevulinic acid and its transformation into coproporphyrinogen in animals and bacteria. In: Biosynthesis of heme and chlorophylls, Dailey HA (Ed), McGraw-Hill, New York 1990. p.55.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/8\">",
"      Podvinec M, Handschin C, Looser R, Meyer UA. Identification of the xenosensors regulating human 5-aminolevulinate synthase. Proc Natl Acad Sci U S A 2004; 101:9127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/9\">",
"      Minder EI. Coproporphyrin isomers in acute-intermittent porphyria. Scand J Clin Lab Invest 1993; 53:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/10\">",
"      Anderson KE, Drummond GS, Freddara U, et al. Porphyrogenic effects and induction of heme oxygenase in vivo by delta-aminolevulinic acid. Biochim Biophys Acta 1981; 676:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/11\">",
"      Wang AL, Arredondo-Vega FX, Giampietro PF, et al. Regional gene assignment of human porphobilinogen deaminase and esterase A4 to chromosome 11q23 leads to 11qter. Proc Natl Acad Sci U S A 1981; 78:5734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/12\">",
"      Chretien S, Dubart A, Beaupain D, et al. Alternative transcription and splicing of the human porphobilinogen deaminase gene result either in tissue-specific or in housekeeping expression. Proc Natl Acad Sci U S A 1988; 85:6.",
"     </a>",
"    </li>",
"    <li>",
"     Grandchamp B, Beaumont C, de Verneuil H, et al. Genetic expression of porphobilinogen deaminase and urod during the erythroid differentiation of mouse erythroleukemic cells. In: Porphyrins and porphyrias, Nordmann Y (Ed), John Libbey &amp; Company, London 1986. p.35.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/14\">",
"      Grandchamp B, De Verneuil H, Beaumont C, et al. Tissue-specific expression of porphobilinogen deaminase. Two isoenzymes from a single gene. Eur J Biochem 1987; 162:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/15\">",
"      Mignotte V, Eleouet JF, Raich N, Romeo PH. Cis- and trans-acting elements involved in the regulation of the erythroid promoter of the human porphobilinogen deaminase gene. Proc Natl Acad Sci U S A 1989; 86:6548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/16\">",
"      Raich N, Romeo PH, Dubart A, et al. Molecular cloning and complete primary sequence of human erythrocyte porphobilinogen deaminase. Nucleic Acids Res 1986; 14:5955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/17\">",
"      Grandchamp B, Picat C, Kauppinen R, et al. Molecular analysis of acute intermittent porphyria in a Finnish family with normal erythrocyte porphobilinogen deaminase. Eur J Clin Invest 1989; 19:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/18\">",
"      Soonawalla ZF, Orug T, Badminton MN, et al. Liver transplantation as a cure for acute intermittent porphyria. Lancet 2004; 363:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/19\">",
"      Seth AK, Badminton MN, Mirza D, et al. Liver transplantation for porphyria: who, when, and how? Liver Transpl 2007; 13:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/20\">",
"      Brennan MJ, Cantrill RC. Delta-aminolaevulinic acid is a potent agonist for GABA autoreceptors. Nature 1979; 280:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/21\">",
"      M&uuml;ller WE, Snyder SH. delta-Aminolevulinic acid: influences on synaptic GABA receptor binding may explain CNS symptoms of porphyria. Ann Neurol 1977; 2:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/22\">",
"      Mustajoki P, Timonen K, Gorchein A, et al. Sustained high plasma 5-aminolaevulinic acid concentration in a volunteer: no porphyric symptoms. Eur J Clin Invest 1992; 22:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/23\">",
"      Lindberg RL, Porcher C, Grandchamp B, et al. Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria. Nat Genet 1996; 12:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/24\">",
"      Meyer UA, Schuurmans MM, Lindberg RL. Acute porphyrias: pathogenesis of neurological manifestations. Semin Liver Dis 1998; 18:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/25\">",
"      Lindberg RL, Martini R, Baumgartner M, et al. Motor neuropathy in porphobilinogen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria. J Clin Invest 1999; 103:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/26\">",
"      Sze G. Cortical brain lesions in acute intermittent porphyria. Ann Intern Med 1996; 125:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/27\">",
"      Lithner F. Could attacks of abdominal pain in cases of acute intermittent porphyria be due to intestinal angina? J Intern Med 2000; 247:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/28\">",
"      Litman DA, Correia MA. Elevated brain tryptophan and enhanced 5-hydroxytryptamine turnover in acute hepatic heme deficiency: clinical implications. J Pharmacol Exp Ther 1985; 232:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/29\">",
"      Louis CA, Sinclair JF, Wood SG, et al. Synergistic induction of cytochrome P450 by ethanol and isopentanol in cultures of chick embryo and rat hepatocytes. Toxicol Appl Pharmacol 1993; 118:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/30\">",
"      Thunell S, Floderus Y, Henrichson A, et al. Alcoholic beverages in acute porphyria. J Stud Alcohol 1992; 53:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/31\">",
"      Lip GY, McColl KE, Goldberg A, Moore MR. Smoking and recurrent attacks of acute intermittent porphyria. BMJ 1991; 302:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/32\">",
"      Bylesj&ouml; I, Wikberg A, Andersson C. Clinical aspects of acute intermittent porphyria in northern Sweden: a population-based study. Scand J Clin Lab Invest 2009; 69:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/33\">",
"      Anderson KE, Freddara U, Kappas A. Induction of hepatic cytochrome P-450 by natural steroids: relationship to the induction of delta-aminolevulinate synthase and porphyrin accumulation in the avian embryo. Arch Biochem Biophys 1982; 217:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/34\">",
"      Anderson KE, Spitz IM, Bardin CW, Kappas A. A gonadotropin releasing hormone analogue prevents cyclical attacks of porphyria. Arch Intern Med 1990; 150:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/35\">",
"      Kauppinen R, Mustajoki P. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine (Baltimore) 1992; 71:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/36\">",
"      Milo R, Neuman M, Klein C, et al. Acute intermittent porphyria in pregnancy. Obstet Gynecol 1989; 73:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/37\">",
"      Shenhav S, Gemer O, Sassoon E, Segal S. Acute intermittent porphyria precipitated by hyperemesis and metoclopramide treatment in pregnancy. Acta Obstet Gynecol Scand 1997; 76:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/38\">",
"      Andersson C, Bylesj&ouml; I, Lithner F. Effects of diabetes mellitus on patients with acute intermittent porphyria. J Intern Med 1999; 245:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/39\">",
"      Handschin C, Lin J, Rhee J, et al. Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. Cell 2005; 122:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/40\">",
"      Wu Z, Puigserver P, Andersson U, et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999; 98:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/41\">",
"      Scassa ME, Guberman AS, Ceruti JM, C&aacute;nepa ET. Hepatic nuclear factor 3 and nuclear factor 1 regulate 5-aminolevulinate synthase gene expression and are involved in insulin repression. J Biol Chem 2004; 279:28082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/42\">",
"      Scassa ME, Guberman AS, Varone CL, C&aacute;nepa ET. Phosphatidylinositol 3-kinase and Ras/mitogen-activated protein kinase signaling pathways are required for the regulation of 5-aminolevulinate synthase gene expression by insulin. Exp Cell Res 2001; 271:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/43\">",
"      WELLAND FH, HELLMAN ES, GADDIS EM, et al. FACTORS AFFECTING THE EXCRETION OF PORPHYRIN PRECURSORS BY PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA. I. THE EFFECT OF DIET. Metabolism 1964; 13:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/44\">",
"      Phillips JD, Kushner JP. Fast track to the porphyrias. Nat Med 2005; 11:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/45\">",
"      Thaler MM, Dawber NH. Stimulation of bilirubin formation in liver of newborn rats by fasting and glucagon. Gastroenterology 1977; 72:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40198/abstract/46\">",
"      Mustajoki P, Heinonen J. General anesthesia in \"inducible\" porphyrias. Anesthesiology 1980; 53:15.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7132 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-61.234.146.186-EA4EE1DDAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_16_40198=[""].join("\n");
var outline_f39_16_40198=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      METABOLIC DEFECT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MOLECULAR PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MECHANISM FOR NEUROLOGICAL DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EXACERBATING FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Drugs and chemicals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Endocrine factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Nutritional factors and stress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other factors and additive effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7132\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7132|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/31/25077\" title=\"figure 1\">",
"      Heme synthesis and porphyria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/50/35617\" title=\"figure 2\">",
"      Heme biosynthetic pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7132|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/1/25627\" title=\"table 1\">",
"      Acute porphyrias features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/6/43116\" title=\"table 2\">",
"      Acute porphyrias drug interactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/12/10439?source=related_link\">",
"      Clinical manifestations and diagnosis of acute intermittent porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/20/3398?source=related_link\">",
"      Management of acute intermittent porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28984?source=related_link\">",
"      Porphyrias: An overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_16_40199="Treatment of primary aldosteronism";
var content_f39_16_40199=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of primary aldosteronism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/16/40199/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/16/40199/contributors\">",
"     William F Young, Jr, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/16/40199/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/16/40199/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/16/40199/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/16/40199/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/16/40199/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/16/40199/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/16/40199/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsuppressible (primary) hypersecretion of aldosterone is an uncommon but underdiagnosed cause of hypertension. The classic presenting signs of primary aldosteronism are hypertension and hypokalemia.",
"   </p>",
"   <p>",
"    Many subtypes of primary aldosteronism have been described since Conn's original report of the aldosterone-producing adenoma in 1954 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The most common subtypes are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aldosterone-producing adenomas",
"     </li>",
"     <li>",
"      Bilateral idiopathic hyperaldosteronism",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Less common forms include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unilateral hyperplasia or primary adrenal hyperplasia (caused by micronodular or macronodular hyperplasia of the zona glomerulosa of predominantly one adrenal gland)",
"     </li>",
"     <li>",
"      Familial hyperaldosteronism type I (glucocorticoid-remediable aldosteronism), type II (the familial occurrence of aldosterone-producing adenoma or bilateral idiopathic hyperplasia or both), and type III due to KCNJ5 potassium channel mutations",
"     </li>",
"     <li>",
"      Pure aldosterone-producing adrenocortical carcinomas and ectopic aldosterone-secreting tumors (eg, neoplasms in the ovary or kidney)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The subtype-directed treatment of primary aldosteronism will be reviewed here. The clinical manifestations and diagnosis of this disorder and other less common causes of mineralocorticoid excess are discussed separately (",
"    <a class=\"graphic graphic_algorithm graphicRef76673 \" href=\"mobipreview.htm?35/23/36222\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37911?source=see_link\">",
"     \"Clinical features of primary aldosteronism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/13/5338?source=see_link\">",
"     \"Approach to the patient with hypertension and hypokalemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/5/22615?source=see_link\">",
"     \"Familial hyperaldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GOALS OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment goal is to prevent the morbidity and mortality associated with hypertension, hypokalemia, renal toxicity, and cardiovascular damage. The cause of primary aldosteronism helps to determine the appropriate treatment. Normalization of blood pressure should not be the only goal. In addition to the kidney and colon, mineralocorticoid receptors occur in the heart, brain, and blood vessels. Excessive secretion of aldosterone is associated with increased risk of cardiovascular disease and morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Therefore, normalization of circulating aldosterone or mineralocorticoid receptor blockade should be part of the management plan for all patients with primary aldosteronism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37911?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features of primary aldosteronism\", section on 'Cardiovascular risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Establishing the correct subtype diagnosis is essential since the treatment of primary aldosteronism is based upon whether the adrenal aldosterone hypersecretion is unilateral (adenoma, unilateral hyperplasia, or carcinoma) or bilateral (idiopathic adrenal hyperplasia or familial hyperaldosteronism).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgery is curative only in patients with unilateral disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Unilateral adrenal adenoma or hyperplasia'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients with bilateral idiopathic adrenal hyperplasia are treated with a mineralocorticoid antagonist. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Idiopathic adrenal hyperplasia'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients with glucocorticoid-remediable aldosteronism should receive physiologic doses of a glucocorticoid. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Glucocorticoid-remediable aldosteronism'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical Guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2008, The Endocrine Society published evidence-based guidelines for the diagnosis and treatment of primary aldosteronism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/5\">",
"     5",
"    </a>",
"    ]. Our therapeutic approach outlined here is consistent with the guidelines. The recommendations for case detection and confirmation of primary aldosteronism are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/13/5338?source=see_link\">",
"     \"Approach to the patient with hypertension and hypokalemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     UNILATERAL ADRENAL ADENOMA OR HYPERPLASIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A unilateral adrenal adenoma is responsible for the hypersecretion of aldosterone in 30 to 60 percent of cases of primary aldosteronism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/2\">",
"     2",
"    </a>",
"    ], while unilateral hyperplasia is less common (about 3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/3\">",
"     3",
"    </a>",
"    ]. Surgery is the preferred therapy in this setting. An alternative is medical therapy with a mineralocorticoid receptor antagonist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unilateral adrenalectomy in patients with aldosterone-producing adenomas or unilateral hyperplasia induces a marked reduction in aldosterone secretion and correction of the hypokalemia in almost all patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/3,6,7\">",
"     3,6,7",
"    </a>",
"    ]. Hypertension is improved in all and is cured in approximately 35 to 60 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/3,6-9\">",
"     3,6-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest laparoscopic adrenalectomy over open adrenalectomy because it is associated with shorter hospital stays and fewer complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laparoscopic partial adrenalectomy (removal of an adenoma leaving the remaining adrenal intact) has been tried as a strategy to further reduce surgical morbidity, but it is an inadequate procedure in many cases. This was illustrated in a series of 92 patients with primary aldosteronism undergoing laparoscopic adrenalectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/13\">",
"     13",
"    </a>",
"    ]. Postoperatively, all 63 patients with total adrenalectomy had improved blood pressure and normal plasma aldosterone, while 2 of 29 with partial adrenalectomy had persistent hypertension and high plasma aldosterone. Of the 63 removed adrenal glands, 17 (27 percent) contained multiple nodules along with what was thought to be the hypersecretory adenoma. Thus, we suggest resection of the entire affected adrenal gland.",
"   </p>",
"   <p>",
"    Preoperatively, hypertension should be controlled and hypokalemia should be corrected with a mineralocorticoid receptor antagonist (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    ). The blood pressure response to spironolactone preoperatively often predicts the blood pressure response to unilateral adrenalectomy in patients with aldosterone-producing adenomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Postoperative management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative management after unilateral adrenalectomy should include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plasma aldosterone should be measured the day after surgery to assess for cure.",
"     </li>",
"     <li>",
"      Potassium supplements and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      should be discontinued and, if possible, antihypertensive therapy should be decreased.",
"     </li>",
"     <li>",
"      Patients should be monitored closely for hyperkalemia, which may result from transient hypoaldosteronism due to chronic suppression of renal renin release and contralateral adrenal gland aldosterone secretion. Serum potassium should be measured during the hospitalization, and as an outpatient, once weekly for four weeks. Occasionally short-term supplementation with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/9/21655?source=see_link\">",
"       fludrocortisone",
"      </a>",
"      may be needed to treat the hyperkalemia.",
"     </li>",
"     <li>",
"      Serum creatinine should be followed serially in patients who had renal insufficiency preoperatively. Primary aldosteronism has been associated with renal toxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/14-16\">",
"       14-16",
"      </a>",
"      ], and improvement of hypertension corrects renal hyperfiltration and may unmask the renal damage. In a long-term study that included 50 patients with primary aldosteronism and 100 patients with essential hypertension, during 30 to 90 days after intervention, the mean glomerular filtration rate decreased in patients with primary aldosteronism by -13.6",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      but only by -2.1",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      in patients with essential hypertension, despite similar blood pressure values [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The preferred intravenous fluid after surgery is isotonic saline without potassium (unless the patient is still hypokalemic) and a sodium-rich diet should be suggested after discharge [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Effect on hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although hypertension is cured in some patients, a lesser degree of hypertension persists in as many as 40 to 65 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/6-9,17\">",
"     6-9,17",
"    </a>",
"    ]. A number of clinical features help to identify patients who are more likely to experience complete resolution of their hypertension after adrenalectomy, including lack of family history of hypertension, shorter duration of hypertension, preoperative use of two or fewer antihypertensive agents, younger age, higher preoperative ratio of plasma aldosterone concentration to plasma renin activity, and higher urine aldosterone level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Persistent hypertension may be related to underlying essential hypertension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the development of nephrosclerosis after a prolonged period of uncontrolled hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/9,18\">",
"     9,18",
"    </a>",
"    ]. It is also possible that an error in subtype assignment has been made and that the patient has bilateral adrenal hyperplasia, a disorder that should be treated medically, not with unilateral adrenalectomy. As many as one-third of patients thought to have a unilateral lesion on imaging studies have bilateral adrenal hyperplasia on adrenal vein sampling (",
"    <a class=\"graphic graphic_algorithm graphicRef76673 \" href=\"mobipreview.htm?35/23/36222\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/13/5338?source=see_link&amp;anchor=H20#H20\">",
"     \"Approach to the patient with hypertension and hypokalemia\", section on 'Adrenal vein sampling'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A scoring system, the aldosteronoma resolution score (ARS), has been proposed to help identify patients at low or high likelihood of complete resolution of hypertension after adrenalectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/19\">",
"     19",
"    </a>",
"    ]. In a study of 100 patients with primary aldosteronism seen at a single tertiary center, four clinical features provided the best predictive model for complete resolution of hypertension after adrenalectomy. For scoring purposes, each predictor was assigned a weight as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Two or fewer antihypertensive medications (2 points)",
"     </li>",
"     <li>",
"      Body mass index &le;25",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      (1 point)",
"     </li>",
"     <li>",
"      Duration of hypertension &le;6 years (1 point)",
"     </li>",
"     <li>",
"      Female sex (1 point)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The likelihood of complete resolution of hypertension for patients with ARS scores of 0 to 1, 2 to 3, and 4 to 5 was 27, 46, and 75 percent, respectively. These relationships were validated in a second population of 67 patients from a different tertiary center. Thus, the ARS appears to be a useful tool for informing patients of the likelihood of resolution of hypertension after surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Ablative procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although published data are limited, some centers have advocated percutaneous ablative therapy for unilateral adrenal adenomas, including percutaneous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    injection and radiofrequency ablation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Percutaneous ablative therapy requires overnight hospitalization. It is also associated with a variety of adverse effects, including abdominal pain, hematuria, pancreatitis, pneumothorax, bleeding, adrenal abscess formation, tumor tracking, and incomplete ablation.",
"   </p>",
"   <p>",
"    Given the limited experience, uncertain success rate, and potential complications, we cannot recommend adrenal percutaneous ablative therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Aldosterone antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although laparoscopic adrenalectomy is more cost-effective over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/22\">",
"     22",
"    </a>",
"    ], the administration of an aldosterone (mineralocorticoid receptor) antagonist is an effective alternative in patients who refuse or are not candidates for surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. The efficacy of this approach was illustrated in a study of 24 patients with adenomas who were treated medically for at least five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/24\">",
"     24",
"    </a>",
"    ]. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systolic and diastolic blood pressures decreased from",
"      <span class=\"nowrap\">",
"       175/106",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       129/79",
"      </span>",
"      mmHg.",
"     </li>",
"     <li>",
"      The serum potassium concentration increased from 3.0 to 4.3",
"      <span class=\"nowrap\">",
"       mEq/L.",
"      </span>",
"     </li>",
"     <li>",
"      Five tumors had increased in size by at least 0.5 cm (as determined by CT scan), but there was no evidence of malignant transformation in any patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dietary sodium restriction (&lt;100",
"    <span class=\"nowrap\">",
"     mEq/day),",
"    </span>",
"    maintenance of ideal body weight, avoidance of alcohol, and regular aerobic exercise contribute to the success of pharmacologic therapy in almost any patient with hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There have been no placebo-controlled, randomized trials evaluating the relative efficacy of different drugs in the management of primary aldosteronism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/25\">",
"     25",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     Spironolactone",
"    </a>",
"    has long been the drug of choice;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    represents a newer more expensive alternative with fewer side effects. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Suggested approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are some precautions with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum potassium and creatinine should be monitored frequently during the first four to six weeks of therapy, especially in patients with renal insufficiency or diabetes mellitus. The clinical course and circumstances dictate the frequency of subsequent monitoring.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       Spironolactone",
"      </a>",
"      may increase the half-life of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      , and for patients taking this drug, the dose may need to be adjusted when treatment with spironolactone is started.",
"     </li>",
"     <li>",
"      Concomitant therapy with salicylates or nonsteroidal antiinflammatory drugs may interfere with the antihypertensive efficacy of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      (and other antihypertensive medications).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     Spironolactone",
"    </a>",
"    is also a progesterone agonist and androgen receptor antagonist, resulting in side effects such as breast tenderness and menstrual irregularities in women, and impotence, decreased libido, and gynecomastia in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In a review of 699 patients with primary aldosteronism treated with spironolactone, the incidence of gynecomastia was dose-dependent: 6.9 percent at doses below 50",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and 52 percent at doses above 150",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/24\">",
"     24",
"    </a>",
"    ]. Spironolactone may also be associated with minor gastrointestinal symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27384?source=see_link\">",
"     \"Causes and evaluation of gynecomastia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"     Eplerenone",
"    </a>",
"    is a highly selective mineralocorticoid receptor antagonist. Compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    , eplerenone has 0.1 percent of the binding affinity to androgen receptors and less than 1 percent of the binding affinity to progesterone receptors.",
"   </p>",
"   <p>",
"    Because of its selectivity,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    is associated with a low incidence of endocrine side effects. This was illustrated in multicenter, randomized, double-blind, active-controlled, and parallel group design study in 141 patients randomized to treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    (75 to 225 mg once daily) or eplerenone (100 to 300 mg once daily) using a titration-to-effect design [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/27\">",
"     27",
"    </a>",
"    ]. Changes from baseline in diastolic blood pressure were less on eplerenone (-5.6 &plusmn; 1.3 SE mmHg) than spironolactone (-12.5 &plusmn; 1.3 SE mmHg) (difference, -6.9 mmHg, 95% CI -10.6, -3.3). Although there were no significant differences between eplerenone and spironolactone in the overall incidence of adverse events, more patients randomized to spironolactone developed male gynecomastia (21.2 versus 4.5 percent) and female mastodynia (21.1 versus 0.0 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/27\">",
"     27",
"    </a>",
"    ]. Because of its short half-life, eplerenone may have been more effective if given twice daily. Thus, until more data become available, it is reasonable to start with spironolactone and, if endocrine side effects are limiting, switch to eplerenone.",
"   </p>",
"   <p>",
"    For patients with primary aldosteronism, a reasonable starting dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    is 25 mg once or twice daily and titrated upward for normokalemia without the aid of potassium supplements. The maximum dose approved by the US Food and Drug Administration for hypertension is 100 mg daily. Eplerenone has 25 to 50 percent less mg per mg potency than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    . Serum potassium and creatinine should be monitored frequently during the first four to six weeks of therapy, especially in patients with renal insufficiency or diabetes mellitus. The clinical course and circumstances dictate the frequency of subsequent monitoring. Eplerenone is now available as a generic, but it remains substantially more expensive than spironolactone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Potassium-sparing diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potassium-sparing diuretics that block the aldosterone-sensitive sodium channel in the collecting tubules (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/60/43973?source=see_link\">",
"     triamterene",
"    </a>",
"    ) can block the renal effects of aldosterone, lowering the blood pressure and raising the serum potassium concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. However, these drugs are not recommended for first-line therapy because of persistence of hyperaldosteronism with its possible deleterious cardiovascular effects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37911?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features of primary aldosteronism\", section on 'Cardiovascular risk'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/13/39128?source=see_link&amp;anchor=H5#H5\">",
"     \"Mechanism of action of diuretics\", section on 'Potassium-sparing diuretics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Suggested approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of medical therapy in patients with unilateral disease who refuse or are not candidates for surgery are correction of hypokalemia, restoration of normal blood pressure, and reversal of the effects of hyperaldosteronism on the heart. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Goals of therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    When using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    or, if not tolerated,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    , we suggest the following regimen, which is consistent with the 2008 Endocrine Society guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       Spironolactone",
"      </a>",
"      is titrated to a normal serum potassium concentration without the aid of potassium supplements. The starting dose is 12.5 to 25 mg daily with food, which increases drug absorption [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/5\">",
"       5",
"      </a>",
"      ]. The dose can be increased every two weeks.",
"     </li>",
"     <li>",
"      The blood pressure goal is often difficult to achieve with monotherapy, since a lesser degree of hypertension persists after surgery in as many as 40 to 65 percent of patients despite complete correction of the hyperaldosteronism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/6-8\">",
"       6-8",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Effect on hypertension'",
"      </a>",
"      above.) If hypertension persists, we add another antihypertensive drug (eg, 12.5 to 25 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"       chlorthalidone",
"      </a>",
"      daily).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/12/38085?source=see_link\">",
"       Amiloride",
"      </a>",
"      is an alternative for men and women intolerant of both",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"       eplerenone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/28\">",
"       28",
"      </a>",
"      ]. Amiloride dosing may be started at 5 mg twice daily and increased to the dose needed to correct the hypokalemia. If the hypertension persists, a second-step drug should be added. Low doses of a thiazide diuretic (eg, 12.5 to 25 mg of hydrochlorothiazide or chlorthalidone daily) are preferred because hypervolemia is a major reason for resistance to amiloride [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/24,25\">",
"       24,25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H379211\">",
"    <span class=\"h4\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;With each medication change, it is important to monitor the effect on both blood pressure and serum potassium. Serum potassium, creatinine, and blood pressure should be monitored frequently during the first four to six weeks of medical therapy (especially in patients with renal insufficiency or diabetes mellitus). Clinical course and circumstances dictate the frequency of monitoring thereafter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     BILATERAL ADRENAL HYPERPLASIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three forms of primary aldosteronism due to bilateral adrenal zona glomerulosa hyperplasia: idiopathic adrenal hyperplasia; the rare glucocorticoid-remediable aldosteronism, which responds to the administration of exogenous glucocorticoid; and type III familial hyperaldosteronism due to germline KCNJ5 potassium channel mutations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/13/5338?source=see_link\">",
"     \"Approach to the patient with hypertension and hypokalemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/5/22615?source=see_link\">",
"     \"Familial hyperaldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Idiopathic adrenal hyperplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic adrenal hyperplasia is generally a milder disease than adrenal adenoma, with less hypersecretion of aldosterone and less hypokalemia. Such patients should be treated with an aldosterone (mineralocorticoid receptor) antagonist.",
"   </p>",
"   <p>",
"    Subtotal adrenalectomy has been tried in patients with idiopathic hyperplasia, but only a minority of patients have a clinically significant hypotensive response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/30\">",
"     30",
"    </a>",
"    ]. However, unilateral adrenalectomy in patients with bilateral adrenal hyperplasia does have the potential to effectively \"debulk\" the amount of adrenal tissue responsible for aldosterone hypersecretion and may, in selected patients, provide improved blood pressure control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Optimal treatment of idiopathic adrenal hyperplasia consists of mineralocorticoid receptor blockade with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    as described above for medical therapy of a unilateral adrenal adenoma. The goals of therapy are the same as for unilateral adenoma: normalization of the serum potassium in hypokalemic patients, normalization of the blood pressure, and reversal of the effects of hyperaldosteronism on the heart (which cannot be confirmed clinically). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Goals of therapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Medical therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In patients with bilateral adrenal hyperplasia, quality of life (QOL), as measured by the validated Medical Outcomes Study Short Form 6 General Health Survey (SF-36), improves during treatment with mineralocorticoid receptor antagonists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/16/40199/abstract/32\">",
"     32",
"    </a>",
"    ]. However, the improvement appears to be more modest and occurs more slowly when compared with historical control patients undergoing unilateral adrenalectomy for unilateral adrenal adenoma.",
"   </p>",
"   <p>",
"    A thiazide diuretic or an angiotensin converting enzyme (ACE) inhibitor can be added if the hypertension persists. The efficacy of an ACE inhibitor in the low plasma renin state may in part reflect the role of even low concentrations of angiotensin II as an aldosterone secretagogue in adrenal hyperplasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Glucocorticoid-remediable aldosteronism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before initiating treatment for glucocorticoid-remediable aldosteronism, the diagnosis should be confirmed with genetic testing; the mutation in patients with GRA is fusion of the promoter region of the gene for CYP11B1 and the coding sequences of CYP11B2. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/5/22615?source=see_link\">",
"     \"Familial hyperaldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic treatment with physiologic doses of a glucocorticoid normalizes blood pressure and corrects hypokalemia. The clinician should be cautious about inducing iatrogenic Cushing's syndrome with excessive doses of glucocorticoids, especially with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    in children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/5/22615?source=see_link&amp;anchor=H8#H8\">",
"     \"Familial hyperaldosteronism\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      From a treatment perspective, the two major forms of primary aldosteronism are: unilateral adrenal aldosterone hypersecretion (eg, adenoma, unilateral hyperplasia, or carcinoma) and bilateral aldosterone hypersecretion (eg, idiopathic adrenal hyperplasia and the rare glucocorticoid-remediable aldosteronism). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Unilateral adrenal adenoma or hyperplasia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Bilateral adrenal hyperplasia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goals of therapy for primary aldosteronism due to either unilateral or bilateral adrenal disease are the same and include: normalization of the serum potassium in hypokalemic patients; normalization of the blood pressure, which often may persist after correction of the hyperaldosteronism; and reversal of the adverse cardiovascular effects of hyperaldosteronism. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Goals of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with confirmed unilateral aldosterone hypersecretion (eg, adrenal adenoma or unilateral adrenal hyperplasia), we suggest unilateral adrenalectomy over medical therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of the reduction in postoperative morbidity, hospital stay, and expense compared with open laparotomy, we suggest laparoscopic adrenalectomy by an experienced endocrine surgeon for adrenal adenomas (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Hypokalemia should be corrected with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      preoperatively. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Surgery'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34390?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment of adrenocortical adenomas\", section on 'Laparoscopic versus open surgery'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend that patients with bilateral adrenal hyperplasia be treated with medical therapy, not adrenalectomy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Blood pressure control is often inadequate with subtotal adrenalectomy, and the risks associated with bilateral adrenalectomy (including the need for lifelong glucocorticoid and mineralocorticoid replacement) outweigh the potential benefits. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Bilateral adrenal hyperplasia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with either bilateral adrenal hyperplasia or confirmed unilateral adrenal aldosterone hypersecretion (who refuse or are not candidates for surgery), we recommend an aldosterone antagonist (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"       eplerenone",
"      </a>",
"      ) over other potassium-sparing diuretics (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/12/38085?source=see_link\">",
"       amiloride",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/60/43973?source=see_link\">",
"       triamterene",
"      </a>",
"      ) as our first choice for pharmacologic therapy (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Aldosterone antagonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Of the aldosterone antagonists, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      as the first line drug (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ) and switch to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"       eplerenone",
"      </a>",
"      if side effects are limiting. Eplerenone is a more selective mineralocorticoid receptor antagonist than spironolactone and is associated with fewer side effects; however, when administered once daily and compared with spironolactone, eplerenone is a less effective antihypertensive agent. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Aldosterone antagonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who do not tolerate",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"       eplerenone",
"      </a>",
"      , we switch to a potassium-sparing diuretic, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/12/38085?source=see_link\">",
"       amiloride",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Potassium-sparing diuretics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serum potassium, creatinine, and blood pressure should be monitored frequently during the first four to six weeks of medical therapy (especially in patients with renal insufficiency or diabetes mellitus). Clinical course and circumstances dictate the frequency of monitoring thereafter. (See",
"      <a class=\"local\" href=\"#H379211\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/1\">",
"      CONN JW. Aldosterone in clinical medicine; past, present, and future. AMA Arch Intern Med 1956; 97:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/2\">",
"      Mattsson C, Young WF Jr. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol 2006; 2:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/3\">",
"      Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf) 2007; 66:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/4\">",
"      Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/5\">",
"      Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:3266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/6\">",
"      Sawka AM, Young WF, Thompson GB, et al. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med 2001; 135:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/7\">",
"      Milsom SR, Espiner EA, Nicholls MG, et al. The blood pressure response to unilateral adrenalectomy in primary aldosteronism. Q J Med 1986; 61:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/8\">",
"      Celen O, O'Brien MJ, Melby JC, Beazley RM. Factors influencing outcome of surgery for primary aldosteronism. Arch Surg 1996; 131:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/9\">",
"      TAIPAI Study Group, Wu VC, Chueh SC, et al. Association of kidney function with residual hypertension after treatment of aldosterone-producing adenoma. Am J Kidney Dis 2009; 54:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/10\">",
"      Duncan JL 3rd, Fuhrman GM, Bolton JS, et al. Laparoscopic adrenalectomy is superior to an open approach to treat primary hyperaldosteronism. Am Surg 2000; 66:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/11\">",
"      Meria P, Kempf BF, Hermieu JF, et al. Laparoscopic management of primary hyperaldosteronism: clinical experience with 212 cases. J Urol 2003; 169:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/12\">",
"      Rossi H, Kim A, Prinz RA. Primary hyperaldosteronism in the era of laparoscopic adrenalectomy. Am Surg 2002; 68:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/13\">",
"      Ishidoya S, Ito A, Sakai K, et al. Laparoscopic partial versus total adrenalectomy for aldosterone producing adenoma. J Urol 2005; 174:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/14\">",
"      Sechi LA, Novello M, Lapenna R, et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA 2006; 295:2638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/15\">",
"      Reincke M, Rump LC, Quinkler M, et al. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J Clin Endocrinol Metab 2009; 94:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/16\">",
"      Sechi LA, Di Fabio A, Bazzocchi M, et al. Intrarenal hemodynamics in primary aldosteronism before and after treatment. J Clin Endocrinol Metab 2009; 94:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/17\">",
"      Meyer A, Brabant G, Behrend M. Long-term follow-up after adrenalectomy for primary aldosteronism. World J Surg 2005; 29:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/18\">",
"      Horita Y, Inenaga T, Nakahama H, et al. Cause of residual hypertension after adrenalectomy in patients with primary aldosteronism. Am J Kidney Dis 2001; 37:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/19\">",
"      Zarnegar R, Young WF Jr, Lee J, et al. The aldosteronoma resolution score: predicting complete resolution of hypertension after adrenalectomy for aldosteronoma. Ann Surg 2008; 247:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/20\">",
"      Minowada S, Fujimura T, Takahashi N, et al. Computed tomography-guided percutaneous acetic acid injection therapy for functioning adrenocortical adenoma. J Clin Endocrinol Metab 2003; 88:5814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/21\">",
"      Munver R, Del Pizzo JJ, Sosa RE. Adrenal-preserving minimally invasive surgery: the role of laparoscopic partial adrenalectomy, cryosurgery, and radiofrequency ablation of the adrenal gland. Curr Urol Rep 2003; 4:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/22\">",
"      Sywak M, Pasieka JL. Long-term follow-up and cost benefit of adrenalectomy in patients with primary hyperaldosteronism. Br J Surg 2002; 89:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/23\">",
"      Lim PO, Jung RT, MacDonald TM. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharmacol 1999; 48:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/24\">",
"      Ghose RP, Hall PM, Bravo EL. Medical management of aldosterone-producing adenomas. Ann Intern Med 1999; 131:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/25\">",
"      Lim PO, Young WF, MacDonald TM. A review of the medical treatment of primary aldosteronism. J Hypertens 2001; 19:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/26\">",
"      Brown JJ, Davies DL, Ferriss JB, et al. Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin. Br Med J 1972; 2:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/27\">",
"      Parthasarathy HK, M&eacute;nard J, White WB, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens 2011; 29:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/28\">",
"      Griffing GT, Cole AG, Aurecchia SA, et al. Amiloride in primary hyperaldosteronism. Clin Pharmacol Ther 1982; 31:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/29\">",
"      Ganguly A, Weinberger MH. Triamterene-thiazide combination: alternative therapy for primary aldosteronism. Clin Pharmacol Ther 1981; 30:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/30\">",
"      Blumenfeld JD, Sealey JE, Schlussel Y, et al. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med 1994; 121:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/31\">",
"      Sukor N, Gordon RD, Ku YK, et al. Role of unilateral adrenalectomy in bilateral primary aldosteronism: a 22-year single center experience. J Clin Endocrinol Metab 2009; 94:2437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/16/40199/abstract/32\">",
"      Ahmed AH, Gordon RD, Sukor N, et al. Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically. J Clin Endocrinol Metab 2011; 96:2904.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 141 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-77.94.48.4-442DE206A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_16_40199=[""].join("\n");
var outline_f39_16_40199=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GOALS OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical Guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      UNILATERAL ADRENAL ADENOMA OR HYPERPLASIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Postoperative management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Effect on hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Ablative procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Aldosterone antagonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Potassium-sparing diuretics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Suggested approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H379211\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      BILATERAL ADRENAL HYPERPLASIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Idiopathic adrenal hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Glucocorticoid-remediable aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/141\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/141|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?35/23/36222\" title=\"algorithm 1\">",
"      Subtype eval primary aldo",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/13/5338?source=related_link\">",
"      Approach to the patient with hypertension and hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27384?source=related_link\">",
"      Causes and evaluation of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/5/22615?source=related_link\">",
"      Familial hyperaldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/13/39128?source=related_link\">",
"      Mechanism of action of diuretics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34390?source=related_link\">",
"      Treatment of adrenocortical adenomas",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_16_40200="Bosentan: Drug information";
var content_f39_16_40200=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bosentan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/53/13141?source=see_link\">",
"    see \"Bosentan: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/8/21641?source=see_link\">",
"    see \"Bosentan: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F142201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tracleer&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F142202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      CO Bosentan;",
"     </li>",
"     <li>",
"      Mylan-Bosentan;",
"     </li>",
"     <li>",
"      PMS-Bosentan;",
"     </li>",
"     <li>",
"      Sandoz-Bosentan;",
"     </li>",
"     <li>",
"      Tracleer&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F142224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Endothelin Antagonist;",
"     </li>",
"     <li>",
"      Vasodilator",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F142205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pulmonary artery hypertension:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &lt;40 kg: Initial and maintenance: 62.5 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &ge;40 kg: Initial: 62.5 mg twice daily for 4 weeks; increase to maintenance dose of 125 mg twice daily. Doses &gt;125 mg twice daily do not appear to confer additional clinical benefit but may increase risk of liver toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     When discontinuing treatment, consider a reduction in dosage to 62.5 mg twice daily for 3-7 days (to avoid clinical deterioration).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Coadministration with protease inhibitor regimen:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Dosage adjustment for concurrent use with atazanavir/ritonavir, darunavir/ritonavir, fosamprenavir, lopinavir/ritonavir, ritonavir, saquinavir/ritonavir, tipranavir/ritonavir:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Coadministration of bosentan in patients currently receiving one of these protease inhibitor regimens for at least 10 days: Begin with bosentan 62.5 mg once daily or every other day based on tolerability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Coadministration of  one of these protease inhibitor regimens in patients currently receiving bosentan: Discontinue bosentan 36 hours prior to the initiation of an above regimen. After at least 10 days of the protease inhibitor regimen, resume bosentan 62.5 mg once daily or every other day based on tolerability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Dosage adjustment for concurrent use with indinavir or nelfinavir:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Coadministration of bosentan in patients currently receiving indinavir or nelfinavir: Begin with bosentan 62.5 mg once daily or every other day based on tolerability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Coadministration of indinavir or nelfinavir in patients currently receiving bosentan: Adjust bosentan to 62.5 mg once daily or every other day based on tolerability",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F2885030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/8/21641?source=see_link\">",
"      see \"Bosentan: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Pulmonary artery hypertension:",
"     </b>",
"     Adolescents &gt;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Canadian labeling (not in U.S. labeling): Children 3-18 years: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-20 kg: Initial: 31.25 mg once daily for 4 weeks; increase to maintenance dose of 31.25 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;20-40 kg: Initial: 31.25 mg twice daily for 4 weeks; increase to maintenance dose of 62.5 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;40 kg: Initial: 62.5 mg twice daily for 4 weeks; increase to maintenance dose of 125 mg twice daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2655957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F142206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F142207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild impairment (Child-Pugh class A): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Moderate-to-severe impairment (Child-Pugh class B and C) and/or baseline transaminase &gt;3 times ULN: Use not recommended; systemic exposure significantly increased in patients with moderate impairment (not studied in patients with severe impairment).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Modification based on transaminase elevation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If any elevation, regardless of degree, is accompanied by clinical symptoms of hepatic injury (unusual fatigue, nausea, vomiting, abdominal pain, fever, or jaundice) or a serum bilirubin &ge;2 times ULN, treatment should be stopped.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AST/ALT &gt;3 times but &le;5 times ULN: Confirm with additional test; if confirmed, reduce dose to 62.5 mg twice daily or interrupt treatment and monitor every 2 weeks. If transaminase levels return to pretreatment values, may continue or reintroduce treatment at the starting dose, as appropriate. When reintroducing treatment, recheck transaminases within 3 days and at least every 2 weeks thereafter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AST/ALT &gt;5 times but &le;8 times ULN: Confirm with additional test; if confirmed, stop treatment. Monitor transaminase levels at least every 2 weeks. May reintroduce treatment, as appropriate, at starting dose, following return to pretreatment values. Recheck within 3 days and at least every 2 weeks thereafter following reinitiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AST/ALT &gt;8 times ULN: Stop treatment and do not reintroduce.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F142181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tracleer&reg;: 62.5 mg, 125 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F142166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11217337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a requirement of the REMS program, access to this medication is restricted. Bosentan (Tracleer&reg;) is only available through Tracleer&reg; Access Program (T.A.P.). Only prescribers and pharmacies registered with T.A.P. may prescribe and dispense bosentan. Further information may be obtained from the manufacturer, Actelion Pharmaceuticals (1-866-228-3546 or file://www.tracleer.com/hcp/prescribing-tracleer.asp).",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089801.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089801.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F142183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food, once in the morning and once in the evening. Women of childbearing potential should avoid excessive handling of broken tablets.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F142182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of pulmonary artery hypertension (PAH) (WHO Group I) in patients with NYHA Class II, III, or IV symptoms to improve exercise capacity and decrease the rate of clinical deterioration",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6053349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Tracleer&reg; may be confused with TriCor&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F142222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Spermatogenesis inhibition (25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hemoglobin decreased (&ge;1 g/dL in up to 57%; &lt;11 g/dL: 3% to 6%; typically in first 6 weeks of therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases increased (&ge;3 times ULN; up to 12%; dose-related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Respiratory tract infection (22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (5%), syncope (5%), flushing (4%), hypotension (4%), palpitation (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Abnormal hepatic function (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Sinusitis (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, angioneurotic edema, heart failure (exacerbation), cirrhosis (prolonged therapy), hyperbilirubinemia, hypersensitivity, jaundice, leukocytoclastic vasculitis, leukopenia, liver failure (rare), neutropenia, peripheral edema, rash, thrombocytopenia, weight gain",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F142186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bosentan or any component of the formulation; concurrent use of cyclosporine or glyburide; pregnancy",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Moderate-to-severe hepatic impairment and/or baseline ALT or AST &gt;3 times the upper limit of normal (ULN), particularly when total bilirubin &gt;2 times ULN",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F142170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluid retention/peripheral edema: Development of peripheral edema due to treatment and/or disease state (pulmonary arterial hypertension) may occur. There have also been postmarketing reports of fluid retention requiring treatment (eg, diuretics, fluid management, hospitalization). Further evaluation may be necessary to determine cause and appropriate treatment or discontinuation of therapy. Use with caution in patients with severe chronic heart failure; associated with increased incidence of hospitalization possibly due to fluid retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic changes: A reduction in hematocrit/hemoglobin may be observed within the first few weeks of therapy with subsequent stabilization of levels. Hemoglobin reductions &gt;15% have been observed in some patients. Measure hemoglobin prior to initiating therapy, at 1 and 3 months, and every 3 months thereafter. Significant decreases in hemoglobin in the absence of other causes may warrant the discontinuation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]:",
"     </b>",
"     <b>",
"      Has been associated with a high incidence (~11%) of significant transaminase elevations (ALT or AST &ge;3 times ULN) with or without elevations in bilirubin and rare cases of unexplained hepatic cirrhosis (after &gt;12 months of therapy) or hepatic failure. Monitor transaminases at baseline then monthly thereafter. Adjust dosage if elevations in liver enzymes occur without symptoms of hepatic injury or elevated bilirubin. Treatment should be stopped in patients who develop elevated transaminases either in combination with symptoms of hepatic injury (unusual fatigue, jaundice, nausea, vomiting, abdominal pain, and/or fever) or elevated bilirubin (&ge;2 times ULN); safety of reintroduction is unknown. Avoid use in patients with baseline serum transaminases &gt;3 times ULN or moderate-to-severe hepatic impairment.",
"     </b>",
"     Transaminase elevations are dose dependent, generally asymptomatic, occur both early and late in therapy, progress slowly, and are usually reversible after treatment interruption or discontinuation. Consider the benefits of treatment versus the risk of hepatotoxicity when initiating therapy in patients with WHO Class II symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Spermatogenesis: Sperm count may be reduced in men during treatment. No changes in sperm function or hormone levels have been noted. Fertility issues may require discussion with patient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary veno-occlusive disease (PVOD): Discontinue in any patient with pulmonary edema suggestive of PVOD.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Bosentan may interact with many medications, resulting in potentially serious and/or life-threatening adverse events (see Drug Interactions).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: May cause birth defects; use in pregnancy is contraindicated. Exclude pregnancy prior to initiation of therapy and obtain pregnancy tests monthly during treatment. Reliable contraception must be used during therapy and for 1 month after stopping treatment. Hormonal contraceptives (oral, injectable, transdermal, or implantable) may not be effective and a second method of contraception (nonhormonal) is required. Patients with tubal ligation or an implanted IUD (Copper T 380A or LNg 20) do not need additional contraceptive measures.",
"     </b>",
"     (See Pregnancy Considerations.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; REMS program:",
"     <b>",
"      [U.S. Boxed Warning]: Because of the risks of hepatic impairment and the high likelihood of teratogenic effects, bosentan is only available through the Tracleer&reg; Access Program (T.A.P.). Patients, prescribers, and pharmacies must be registered with and meet conditions of T.A.P.",
"     </b>",
"     Call 1-866-228-3546 or visit file://www.tracleer.com/hcp/prescribing-tracleer.asp for more information.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F142217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (major), CYP3A4 (major), SLCO1B1;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Induces",
"     </b>",
"     CYP2C9 (strong), CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F142174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Bosentan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Bosentan. Bosentan may decrease the serum concentration of Atazanavir. Management: Concurrent use of atazanavir (without ritonavir) and bosentan is not recommended.  Bosentan dose adjustments are required when used together with atazanavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Bosentan. Bosentan may decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Bosentan. Management: Use bosentan 62.5 mg/day or every other day in adults who have been on elvitegravir/cobicistat/emtricitabine/tenofovir for at least 10 days.  Stop bosentan for at least 36 hrs before starting the combo product; wait at least 10 days before restarting.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Bosentan may decrease the serum concentration of Contraceptives (Estrogens).  Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Bosentan may decrease the serum concentration of Contraceptives (Progestins).  Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Bosentan may decrease the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Bosentan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inducers (Strong) may increase the metabolism of CYP2C9 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: Bosentan may decrease the serum concentration of Darunavir. Darunavir may increase the serum concentration of Bosentan.  Management: Use bosentan 62.5 mg/day or every other day in adult patients taking darunavir/ritonavir for at least 10 days.  Temporarily stop bosentan (for at least 36 hrs) before starting darunavir/ritonavir; wait at least 10 days before restarting bosentan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inducers (Strong) may decrease the serum concentration of Diclofenac (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: Bosentan may decrease the serum concentration of Fosamprenavir. Fosamprenavir may increase the serum concentration of Bosentan.  Management: Use bosentan 62.5 mg/day or every other day in adult patients taking fosamprenavir for at least 10 days.  Temporarily stop bosentan (for at least 36 hrs) before starting fosamprenavir; wait at least 10 days before restarting bosentan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers.  Carefully monitor clinical response and development of adverse reactions.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GlyBURIDE: May enhance the hepatotoxic effect of Bosentan. Bosentan may increase the metabolism of GlyBURIDE. GlyBURIDE may increase the metabolism of Bosentan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Bosentan may increase the metabolism of HMG-CoA Reductase Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Fluvastatin; Pravastatin; Rosuvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Bosentan may decrease the serum concentration of Indinavir. Indinavir may increase the serum concentration of Bosentan.  Management: Initiate bosentan at, or adjust bosentan to, 62.5 mg once daily or every other day (based on tolerability) in indinavir-treated patients (see ritonavir for dosing if that agent is used). Additionally, monitor for possible reduced response to indinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: Bosentan may decrease the serum concentration of Lopinavir. Lopinavir may increase the serum concentration of Bosentan.  Management: Use bosentan 62.5 mg/day or every other day in adult patients taking lopinavir/ritonavir for at least 10 days.  Temporarily stop bosentan (for at least 36 hrs) before starting lopinavir/ritonavir; wait at least 10 days before restarting bosentan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: Bosentan may decrease the serum concentration of Nelfinavir. Nelfinavir may increase the serum concentration of Bosentan.  Management: Initiate bosentan at, or adjust bosentan dose to, 62.5 mg once daily or every other day (based on tolerability) in patients who receive nelfinavir.  Additionally, monitor for possible reduced clinical response to nelfinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NIFEdipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.  Management: Consider alternatives to nifedipine for patients who are using strong CYP3A4 inducers.  At least one specific brand of nifedipine (Adalat CC) lists this combination as contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Avoid use of perampanel with strong CYP3A inducers other than enzyme-inducing antiepileptic drugs (EIAEDs).  Increase perampanel starting dose to 4 mg/day when used with EIAEDs such as phenytoin, carbamazepine, or oxcarbazepine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: Bosentan may decrease the serum concentration of Phosphodiesterase 5 Inhibitors. Phosphodiesterase 5 Inhibitors may increase the serum concentration of Bosentan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Bosentan. Following the initial several weeks of concurrent rifampin, this effect is most likely. Rifampin may increase the serum concentration of Bosentan. This effect is most likely to be observed within the initial few weeks of concurrent therapy (and may be greatest immediately following initiation of the combination). Management: Weekly monitoring of liver function tests during the first 4 weeks of concurrent therapy is recommended, with a return to normal recommended monitoring thereafter as appropriate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May increase the serum concentration of Bosentan. Management: Use bosentan 62.5 mg daily or every other day in adult patients who have been on ritonavir for at least 10 days.  Temporarily stop bosentan (for at least 36 hrs) before starting ritonavir; wait until at least 10 days on ritonavir before restarting.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: Bosentan may decrease the serum concentration of Saquinavir. Saquinavir may increase the serum concentration of Bosentan.  Management: Use bosentan 62.5 mg/day or every other day in adult patients taking saquinavir/ritonavir for at least 10 days.  Temporarily stop bosentan (for at least 36 hrs) before starting saquinavir/ritonavir; wait at least 10 days before restarting bosentan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Bosentan may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Bosentan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Bosentan may decrease the serum concentration of Tipranavir. Tipranavir may increase the serum concentration of Bosentan.  Management: Use bosentan 62.5 mg/day or every other day in adult patients taking tipranavir/ritonavir for at least 10 days.  Temporarily stop bosentan (for at least 36 hrs) before starting tipranavir/ritonavir; wait at least 10 days before restarting bosentan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Bosentan may increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F142197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Bioavailability of bosentan is not affected by food. Bosentan serum concentrations may be increased by grapefruit juice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid St John's wort (may decrease serum concentrations of bosentan).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F142176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F142187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: May cause birth defects; use in pregnancy is contraindicated. Exclude pregnancy prior to initiation of therapy and obtain pregnancy tests monthly during treatment. Reliable contraception must be used during therapy and for 1 month after stopping treatment. Hormonal contraceptives (oral, injectable, transdermal, or implantable) may not be effective and a second method of contraception (nonhormonal) is required. Patients with tubal ligation or an implanted IUD (Copper T 380A or LNg 20) do not need additional contraceptive measures.",
"     </b>",
"     When a hormonal or barrier contraceptive is used, one additional method of contraception is still needed if a male partner has had a vasectomy. When initiating treatment for women of reproductive potential, a negative pregnancy test should be documented within the first 5 days of a normal menstrual period and &ge;11 days after the last unprotected intercourse. A missed menses or suspected pregnancy should be reported to a healthcare provider and prompt immediate pregnancy testing. Sperm counts may be reduced in men during treatment. Women of childbearing potential should avoid splitting, crushing, or handling broken tablets and exposure to the generated dust (tablet splitting is currently outside of product labeling).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F142211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15403558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential risk of adverse events in a nursing infant, a decision should be made to discontinue nursing or discontinue therapy.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F142188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food. Avoid grapefruit and grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tracleer Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     62.5 mg (60): $7992.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg (60): $7992.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F142178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum transaminase (AST and ALT) and bilirubin should be determined prior to the initiation of therapy and at monthly intervals thereafter. Monitor for clinical signs and symptoms of liver injury (eg, abdominal pain, fatigue, fever, jaundice, nausea, vomiting). Hemoglobin and hematocrit should be measured at baseline, at 1 month and 3 months of treatment, and every 3 months thereafter (generally stabilizes after 4-12 weeks of treatment).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A woman of childbearing potential must have a negative pregnancy test prior to the initiation of therapy and monthly thereafter (prior to shipment of monthly refill).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Tracleer (AT, AU, BE, BR, CH, CL, CO, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HK, HN, IE, IL, IT, KP, MY, NL, NO, NZ, PT, SE, SG, TH, TW);",
"     </li>",
"     <li>",
"      Usenta (AR, CN, PE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F142169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks endothelin receptors on vascular endothelium and smooth muscle. Stimulation of these receptors is associated with vasoconstriction. Although bosentan blocks both ET",
"     <sub>",
"      A",
"     </sub>",
"     and ET",
"     <sub>",
"      B",
"     </sub>",
"     receptors, the affinity is higher for the A subtype.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F142185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~18 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: &gt;98% primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP2C9 and 3A4 to three primary metabolites (one contributing ~10% to 20% pharmacologic activity); autoinduction may occur with chronic dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 5 hours; prolonged with heart failure, possibly in PAH",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 3-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (as metabolites); urine (&lt;3% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Badesch DB, Abman SH, Simonneau G, et al, &ldquo;Medical Therapy for Pulmonary Arterial Hypertension: Updated ACCP Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2007, 131(6):1917-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/16/40200/abstract-text/17565025/pubmed\" id=\"17565025\" target=\"_blank\">",
"        17565025",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barst RJ, Ivy D, Dingemanse J, et al, &ldquo;Pharmacokinetics, Safety, and Efficacy of Bosentan in Pediatric Patients With Pulmonary Arterial Hypertension,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2003, 73(4):372-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/16/40200/abstract-text/12709727/pubmed\" id=\"12709727\" target=\"_blank\">",
"        12709727",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McLaughlin VV, Archer SL, Badesch DB, et al, &ldquo;ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in Collaboration with the American College of Chest Physicians, American Thoracic Society, Inc, and the Pulmonary Hypertension Association,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 53(11):1573-619.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/16/40200/abstract-text/19389575/pubmed\" id=\"19389575\" target=\"_blank\">",
"        19389575",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosenzweig EB, Ivy DD, Widlitz A, et al, &ldquo;Effects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005,  46(4):697-704.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/16/40200/abstract-text/16098438/pubmed\" id=\"16098438\" target=\"_blank\">",
"        16098438",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9254 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-6B4A64F196-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_16_40200=[""].join("\n");
var outline_f39_16_40200=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708663\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142201\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142202\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142224\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142205\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2885030\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2655957\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142206\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142207\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142181\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142166\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11217337\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874386\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142183\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142182\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6053349\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142222\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142186\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142170\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142217\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142174\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142197\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142176\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142187\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142211\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15403558\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142188\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323024\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142178\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038542\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142169\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142185\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9254\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9254|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/53/13141?source=related_link\">",
"      Bosentan: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/8/21641?source=related_link\">",
"      Bosentan: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_16_40201="Intermediate case 17 answer";
var content_f39_16_40201=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    Monomorphic ventricular tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This wide complex arrhythmia shows a right bundle branch block morphology with a positive QRS in lead V1. The QS waves in V5 and V6 suggest that the tachycardia originates in the vicinity of an apical-lateral infarct. The diagnosis of VT, rather than supraventricular tachycardia (SVT) with aberration, is supported by the wide R wave in V1 (versus an rSR' pattern which can be seen with SVT or occasionally VT), the very wide QRS (&gt;160 msec, 200 msec here), and the QS waves in V5 and V6. Atrial activity cannot be readily identified in this ECG.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_16_40201=[""].join("\n");
var outline_f39_16_40201=null;
var title_f39_16_40202="Cutaneous lichen planus histopathology";
var content_f39_16_40202=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F82025%7EDERM%2F58826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F82025%7EDERM%2F58826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Cutaneous lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This specimen from a lesion of cutaneous lichen planus demonstrates a band-like lymphocytic infiltrate, saw-tooth rete ridges, multiple apoptotic keratinocytes, and wedge-shaped hypergranulosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cutaneous lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 402px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A marked interface dermatitis resulting in vacuolization of the basal layer is present in this pathologic specimen from a lesion of lichen planus. Hypergranulosis is also present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_16_40202=[""].join("\n");
var outline_f39_16_40202=null;
var title_f39_16_40203="Diff diagnosis Meniere disease";
var content_f39_16_40203=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F63235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F63235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis for Meniere disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Central nervous system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acoustic neuroma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vascular loop compression of eighth nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Basilar/vertebral artery insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arnold-Chiari malformation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebellar tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transient ischemic attacks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Peripheral vestibular system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benign positional vertigo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syphilitic endolymphatic hydrops",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Post-concussive hydrops",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Post-infectious hydrops (history of sudden sensorineural hearing loss, chronic otitis media, or labyrinthitis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoimmune inner ear disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perilymphatic fistula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Otosclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Migraine induced vertigo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyroid disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cogan's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anemia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_16_40203=[""].join("\n");
var outline_f39_16_40203=null;
var title_f39_16_40204="Syndromic hereditary neurop II";
var content_f39_16_40204=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of hereditary peripheral neuropathies associated with other disorders-II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"20%\">",
"     </colgroup>",
"     <colgroup width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Inheritance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chromosome (gene)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Mitochondrial disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leigh's syndrome",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        9q34 (SURF1)",
"       </td>",
"       <td>",
"        Onset in infancy or childhood, developmental delay, psychomotor regression, brainstem dysfunction, ataxia, dystonia, external ophthalmoplegia, seizures, weakness, lactic acidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leber's hereditary optic neuropathy",
"       </td>",
"       <td>",
"        mtDNA",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Affects young adult males, usual onset in late teens, severe permanent visual loss, tremor, multiple sclerosis-like illness, extrapyramidal syndrome, seizures, ataxia, spasticity, mental retardation, peripheral neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        DNA repair disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Xeroderma pigmentosa",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        (XPA-XPG) (XPV)",
"       </td>",
"       <td>",
"        Peripheral neuropathy, photosensitivity, cutaneous malignancy, skin atrophy and telangiectasia, keratitis, opacification of the cornea, iritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cockayne syndrome",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        (CS-A) (CS-B)",
"       </td>",
"       <td>",
"        Progressive dementia, large ears and sunken eyes, physical and mental retardation, short stature, microcephaly, progressive neurologic dysfunction, optic atrophy, photosensitivity without increased frequency of cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ataxia telangiectasia",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        11q22.3 (ATM)",
"       </td>",
"       <td>",
"        Progressive cerebellar ataxia, oculocutaneous telangiectasias, immune deficiency, increased risk of malignancy, radiation sensitivity, diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Hereditary tyrosinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Type I",
"       </td>",
"       <td>",
"        AR",
"       </td>",
"       <td>",
"        (FAH)",
"       </td>",
"       <td>",
"        Severe progressive liver disease, renal tubular dysfunction, peripheral neuropathy, extensor hypertonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Type II",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Keratitis, palmoplantar hyperkeratosis, mental retardation, elevated blood tyrosine concentrations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Type III",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Hypertyrosinemia, mental retardation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AR: autosomal recessive; mtDNA: mitochondrial DNA; XPA-XPG: xeroderma pigmentosa A-G; XPV: xeroderma pigmentosa variant; ATM: ataxia telangiectasia mutated; FAH: fumarylacetoacetate hydrolase.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_16_40204=[""].join("\n");
var outline_f39_16_40204=null;
var title_f39_16_40205="Pharmacology benzodiazepines";
var content_f39_16_40205=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F65653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F65653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pharmacology of benzodiazepines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adult oral dose",
"        <br/>",
"        (mg)*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comparative potency",
"        <br/>",
"        (mg)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Onset after oral dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Metabolism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Elimination half-life",
"        <br/>",
"        (hours)",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Used primarily to treat anxiety disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alprazolam",
"       </td>",
"       <td>",
"        0.5-4",
"       </td>",
"       <td rowspan=\"2\">",
"        0.5",
"        <br/>",
"       </td>",
"       <td rowspan=\"2\">",
"        Intermediate",
"       </td>",
"       <td rowspan=\"2\">",
"        Hepatic by CYP3A4 oxidation. One metabolite possesses partial activity.",
"       </td>",
"       <td rowspan=\"2\">",
"        12-15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alprazolam extended release",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        0.5-6 once daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clonazepam",
"       </td>",
"       <td>",
"        0.5-4",
"       </td>",
"       <td>",
"        0.25-0.5",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"       <td>",
"        Hepatic by CYP3A4 oxidation. No active metabolite.",
"       </td>",
"       <td>",
"        18-50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lorazepam",
"       </td>",
"       <td>",
"        <p>",
"         0.5-6",
"        </p>",
"        <p>",
"         0.5-4 (hypnotic)",
"        </p>",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"       <td>",
"        Hepatic by glucuronidation (rapid). No active metabolite.",
"       </td>",
"       <td>",
"        10-14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oxazepam",
"       </td>",
"       <td>",
"        <p>",
"         30-120",
"        </p>",
"        <p>",
"         15-30 (hypnotic)",
"        </p>",
"       </td>",
"       <td>",
"        15-30",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"       <td>",
"        Hepatic by glucuronidation (rapid). No active metabolite.",
"       </td>",
"       <td>",
"        5-15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chlordiazepoxide",
"       </td>",
"       <td>",
"        5-100",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"       <td>",
"        Hepatic by CYP3A4 oxidation to active metabolites.",
"       </td>",
"       <td>",
"        30-100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diazepam",
"       </td>",
"       <td>",
"        4-40",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        Rapid",
"       </td>",
"       <td>",
"        Hepatic by CYP2C19 and 3A4 oxidation. Multiple active metabolites.",
"       </td>",
"       <td>",
"        50-100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clorazepate",
"       </td>",
"       <td>",
"        7.5-60",
"       </td>",
"       <td>",
"        7.5",
"       </td>",
"       <td>",
"        Rapid",
"       </td>",
"       <td>",
"        Hepatic by CYP3A4 oxidation to active metabolite. Requires acidity for activation of parent compound.",
"       </td>",
"       <td>",
"        36-200",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prazepam",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        10-60",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        Slow",
"       </td>",
"       <td>",
"        Hepatic by CYP3A4 oxidation. Multiple active metabolites. Extensive first-pass metabolism.",
"       </td>",
"       <td>",
"        30-200",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Used primarily to treat insomnia",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Triazolam",
"       </td>",
"       <td>",
"        0.125-0.25",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        Rapid",
"       </td>",
"       <td>",
"        Hepatic by rapid CYP3A4 hydroxylation. No active metabolite.",
"       </td>",
"       <td>",
"        2-5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Estazolam",
"       </td>",
"       <td>",
"        1-2",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"       <td>",
"        Hepatic by CYP3A4 oxidation. No active metabolite.",
"       </td>",
"       <td>",
"        10-24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Temazepam",
"       </td>",
"       <td>",
"        15-30",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"       <td>",
"        Hepatic by UGT2B7, 2C19, 3A4 glucuronidation. No active metabolite.",
"       </td>",
"       <td>",
"        10-40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flurazepam",
"       </td>",
"       <td>",
"        15-30",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"       <td>",
"        Hepatic by CYP3A4 oxidation to active metabolites.",
"       </td>",
"       <td>",
"        40-114",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Quazepam",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"       <td>",
"        Hepatic by CYP3A4 (major) and 2C19 (minor) oxidation to active metabolites.",
"       </td>",
"       <td>",
"        28-114",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Data on drug metabolism and activity of metabolite(s) are for assessment of potential for drug interactions and risk of accumulation. Risk of accumulation is greater, and dose reduction necessary, for older or debilitated adults and for patients with renal or hepatic insufficiency.",
"    <div class=\"footnotes\">",
"     * Range of usual effective total daily dose for adults. Dosages usually given in divided doses two to four times daily for anxiety or panic.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Important: data shown are for comparing potencies and are NOT recommendations for initation of therapy or for conversion between agents.",
"      <br>",
"       &Delta; Half-life of parent drug and active metabolite(s), if any.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        Give once daily in am; do not crush, break, or chew. Duration of effect longer than predicted by half-life due to extended release.",
"        <br>",
"         &sect; Not available in US or Canada.",
"         <br>",
"          &yen; Range of usual effective hypnotic dose for adults, given once daily at bedtime.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_16_40205=[""].join("\n");
var outline_f39_16_40205=null;
var title_f39_16_40206="Ultrathin pancreatoscope ERCP";
var content_f39_16_40206=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancreatoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radiologic view of an ultrathin pancreatoscope in the pancreatic duct.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jurgen F Riemann, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_16_40206=[""].join("\n");
var outline_f39_16_40206=null;
var title_f39_16_40207="Central calcification on CT";
var content_f39_16_40207=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary nodule with central calcification",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 310px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sharply defined solitary pulmonary nodule with smooth border and target-like central calcification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_16_40207=[""].join("\n");
var outline_f39_16_40207=null;
